Former US Assistant Health Secretary Dr. Joxel Garcia Joins FluroTest as CMO and Executive Team Member
New CMO Preps Aggressive SARS-CoV-2 Global Testing and Education Agenda as Company Confirms Variant Detection Capabilities in High-Volume Testing System
FluroTech LTD. and wholly owned subsidiary FluroTest Diagnostic Systems, a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, are pleased to announce the appointment of former U.S. Public Health Service and Four-Star Admiral Joxel Garcia, M.D. to Chief Medical Officer (CMO). Dr. Garcia will be responsible for expanding FluroTest’s domestic and international reach while driving the advancement of the Company’s diagnostic testing solutions. Previously, Dr. Garcia had been functioning in an advisory capacity to the Company as announced April 6, 2021.
FluroTest also now confirms that its testing system will detect primary variants of concern from live viral samples circulating today. The variants detected include B.1.1.7 commonly referred to as the ‘U.K.’ or ‘Alpha’ variant, B.1.351 commonly referred to as the ‘South African’ or ‘Beta’ variant and P.1 and P.2 or ‘Brazilian’ or ‘Gamma’ variants. Under Dr. Garcia’s guidance, FluroTest is closely following International Health Regulations (IHR), the only international and legally-binding treaty empowering the World Health Organization (WHO) to act as the main global surveillance system to control the spread of COVID-19 and other pathogens across 196 countries.
“Testing will remain absolutely essential to reopening society and reinvigorating social and economic activity without fear of risk,” said Dr. Joxel Garcia, FluroTest Chief Medical Officer. “Globally, the pandemic is actually advancing as more hostile virus variants are taking root where vaccination efforts are slow or inconsistent. Having personally helped construct the IHR during my service with the WHO, we know that strengthening virologic global surveillance at local and national levels, as well as international ports of entry like airports and ground crossings, remains a big part of a comprehensive strategy to control COVID-19. I’m actively speaking with global health leads across government and industry about these issues, as the opportunity to utilize FluroTest to support IHR, open commerce and trade between nations and create greater health equity are real and are available now.”
An internationally respected healthcare leader in public health administration, equity and education, Dr. Garcia will increase his support and visibility in FluroTest business operations, reporting directly to CEO Bill Phelan. As the 14th Assistant Secretary for Health, Dr. Garcia operated as the lead advisor on national global public health and science matters for the Secretary of Health. He has also served as United States Representative to the World Health Organization Executive Board, and Deputy Director of the Pan American Health Organization, Regional Office for the Western Hemisphere for the World Health Organization during the 2003 SARS epidemic.
“Joxel’s desire to assume the role of Chief Medical Officer is significant, as we can further leverage his time, expertise and relationship-building efforts to expand our presence in testing markets around the world,” said Bill Phelan, CEO of FluroTest. “The fragility of our social and economic infrastructure continues to fuel our determination to help reopen society safely through mass testing. FluroTest is more than a testing solution, as it helps bring health equity to all people, providing fast, reliable, efficient and cost-effective testing of COVID-19 and other emerging viruses.”
FluroTest’s high-volume antigen system is designed to facilitate very fast and accurate point of access testing of individuals by leveraging the disciplines of robotics automation, biochemistry, fluorescence detection and cloud computing. High-risk pandemic environments supported will include athletic stadiums and performance venues, airline and cruise ship terminals, corporate campuses, manufacturing facilities, schools and colleges, hospitals and large healthcare facilities, transportation and distribution hubs and other large businesses. FluroTest is presently engaged in clinical trials and plans submissions for Emergency Use Authorization (“EUA”) from the U.S. Food and Drug Administration (“FDA”) and from Health Canada for an Interim Order Authorization.
Readers are cautioned that, although FluroTest has achieved proof of concept prototype, the testing method and device is still in the pre-approval stage and accordingly FluroTest is not currently making any express or implied claims that the technology can, or will be able to, accurately detect the COVID-19 virus.